Adverse events associated with mirabegron 50mg versus placebo: A systematic review and meta-analysis.

Hou, J; Xu, F; Du, H; Li, N

Hou, J; Xu, F; Du, H; Li, N.

Afiliación

Hou J; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China.
Xu F; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China.
Du H; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China.
Li N; Department of Urology, Fourth Affiliated Hospital, China Medical University, 4 Chong Shan East Road, Shenyang, Liaoning, China. Electronic address: air-nick@hotmail.com.

Prog Urol ; 31(11): 627-633, 2021 Sep.

Article en En | MEDLINE | ID: mdl-34312078

Asunto(s)

Vejiga Urinaria Hiperactiva; Agentes Urológicos; Acetanilidas/efectos adversos; Humanos; Tiazoles/efectos adversos; Resultado del Tratamiento; Vejiga Urinaria Hiperactiva/tratamiento farmacológico

Palabras clave

Adverse events; Essai randomisé; Meta-analysis; Mirabegron; Méta-analyse; Nasopharyngitis; Safety; Syndrome d'hyperactivité vésicale

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vejiga Urinaria Hiperactiva / Agentes Urológicos Tipo de estudio: Clinical_trials / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Prog Urol Asunto de la revista: UROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google